Genmab A/S Return on Equity

Genmab A/S (GNMSF) currently reports a ROE of 16.02%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Genmab A/S's ROE history and peer comparisons.

Genmab A/S's ROE of 16.02% is higher than the Healthcare sector average of -75.59%. That is roughly 121.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Genmab A/S's current 16.02% should be judged against Healthcare norms (sector average: -75.59%) and against GNMSF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 16.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Genmab A/S, and consider following GNMSF for alerts when major investors trade the stock.

Genmab A/S is classified in the Healthcare sector. On ROE, it currently shows 16.02% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNMSF with unrelated industries.